Targeting macrophage-recruiting chemokines as a novel therapeutic strategy to prevent the progression of solid tumors

Research output: Contribution to journalReview articlepeer-review

Abstract

Solid tumors are initiated by genetic mutations in non-hematopoietic cells and progress into invasive malignant tumors. This tumor progression often culminates in metastatic disease that is largely refractory to current therapeutic modalities and thus dramatically reduces survival of tumor patients. As solid tumors account for more than 80% of cancer-related deaths, it is necessary to develop novel therapeutic strategies to treat the diseases. An attractive strategy is to target macrophages in both primary tumors [known as tumor-associated macrophages (TAMs)] and metastatic tumors [called metastasis-associated macrophages (MAMs)]. TAMs and MAMs are abundant in most solid tumors and can promote tumor metastasis. Several studies in various models of solid tumors suggest that the accumulation of TAMs, MAMs, and their progenitor cells is regulated by chemokine ligands released by tumor and stromal cells. Consequently, these macrophage-recruiting chemokines could be potential therapeutic targets to prevent malignant tumor development through disruption of the accumulation of pro-metastatic macrophages. This review will discuss the role of chemokine ligands and their receptors in TAM and MAM accumulation in primary and secondary tumor sites, and finally discuss the therapeutic potential of inhibitors against these macrophage-recruiting chemokines.

Original languageEnglish
Pages (from-to)2629
JournalFrontiers in Immunology
Volume9
Early online date13 Nov 2018
DOIs
Publication statusPublished - 13 Nov 2018

Fingerprint

Dive into the research topics of 'Targeting macrophage-recruiting chemokines as a novel therapeutic strategy to prevent the progression of solid tumors'. Together they form a unique fingerprint.

Cite this